Latest stories on TTRX
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
StockTitan56 · neutralgeneral
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics appoints Redfield as Chief Scientific Officer
The Fly56 · neutralgeneral
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
StockTitan63 · neutralgeneral
Turn Therapeutics announces publication of peer-reviewed research on GX-03
The Fly56 · neutralproduct/pr
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance
TipRanks34 · bearishgeneral
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics Inc. GAAP EPS of -$0.20
Seeking Alpha34 · bearishearnings
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
StockTitan59 · neutralearnings
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline
TipRanks56 · neutralproduct/pr
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
StockTitan55 · neutralgeneral
Turn Therapeutics Advances Gx 03 Phase 2 Eczema Program
TipRanks63 · neutralproduct/pr
Turn Therapeutics Inc. (TTRX) files 8-K
SEC 8-K50 · neutralgeneral
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data
TipRanks63 · neutralproduct/pr
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data
TipRanks73 · bullishproduct/pr
Turn Therapeutics highlights GX-03 preclinical data in dermatitis
TipRanks56 · neutralproduct/pr